Great Point Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Great Point Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.32M	Buy	+500,000	New	+$8.28M	2.14%	17
2023 Q2	–	Sell	-278,334	Closed	-$5.95M	–	48
2023 Q1	$5.95M	Sell	278,334 -364,232	-57%	-$6.12M	1.17%	26
2022 Q4	$6.75M	Buy	642,566 +150,566	+31%	+$1.34M	1.32%	27
2022 Q3	$3.82M	Buy	492,000 +60,000	+14%	+$424K	0.92%	28
2022 Q2	$2.27M	Buy	+432,000	New	+$2.72M	0.54%	33

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Great Point Partners's MLTX Position: Q1 2026 in Review

Great Point Partners opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 500,000 shares worth $9.32M. The stake represents 2.14% of the portfolio and ranks #17 among its holdings. This is a return to the name: Great Point Partners previously reported a position in MLTX as recently as Q1 2023.

Great Point Partners first reported a position in MLTX in Q2 2022 and has held it in 5 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Great Point Partners held 500,000 shares of MoonLake Immunotherapeutics worth $9.32M as of Q1 2026.
MoonLake Immunotherapeutics was a new Great Point Partners position in Q1 2026.
MoonLake Immunotherapeutics made up 2.14% of Great Point Partners's portfolio in Q1 2026, its #17 holding.
Great Point Partners first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 5 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.